The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Open accessAbstract
Adoptive cell therapy has emerged as a powerful treatment for advanced cancers resistant to conventional agents. Most notable are the remarkable responses seen in patients receiving autologous CD19-redirected chimeric antigen receptor (CAR) T cells for the treatment of B lymphoid malignancies; however, the generation of autologous products for each patient is logistically cumbersome and has restricted widespread clinical use. A banked allogeneic product has the potential to overcome these limitations, yet allogeneic T-cells (even if human leukocyte antigen-matched) carry a major risk of graft-versus-host disease (GVHD). Natural killer (NK) cells are bone marrow-derived innate lymphocytes that can eliminate tumors directly, with their activity governed by the integration of signals from activating and inhibitory receptors and from cytokines including IL-15, IL-12, and IL-18. NK cells do not cause GVHD or other alloimmune or autoimmune toxicities and thus, can provide a potential source of allogeneic "off-the-shelf" cellular therapy, mediating major anti-tumor effects without inducing potentially lethal alloreactivity such as GVHD. Given the multiple unique advantages of NK cells, researchers are now exploring the use of CAR-engineered NK cells for the treatment of various hematological and non-hematological malignancies. Herein, we review preclinical data on the development of CAR-NK cells, advantages, disadvantages, and current obstacles to their clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“For instance, in earlier trials of gene therapy with CD34+ hematopoietic cells for X-linked severe combined immunodeficiency (SCID), 2 of the 10 treated children developed acute leukemia in one study (159) and 1 of the 4 children in another study (160).”
ResultActivating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · cited 1×
“19 gene to redirect specificity to CD19; (ii) produces IL-15 ectopically—a cytokine crucial for NK cell survival and proliferation (219); and (iii) incorporates inducible caspase-9 (iCasp9)—a suicide gene, which can be activated pharmacologically to eliminate CAR cells, as needed (203, 219).”
BackgroundKochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin
Intlekofer, A. M., Takemoto, N., Wherry, E. J., Longworth, S. A., Northrup, J. T., Palanivel, V. R., Mullen, A. C., Gasink, C. R., Kaech, S. M., Miller, J. D., et al. (2005) · Nature Immunology · doi:10.1038/ni1268 · Cited by 1,266
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
MHC class I molecules and kirs in human history, health and survival
Parham, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1570 · Cited by 1,203
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,161
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156 · cited 1×
“Given the recent safety concerns such as cytokine release syndrome and neurotoxicity associated with infusion of CAR-modified T cells (196, 197) (and possibly NK cells), careful consideration of whether a suicide system should be incorporated into the construct as a safety measure is needed.”
BackgroundSavoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., et al. (2002) · Science · doi:10.1126/science.1070104 · Cited by 975
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Miller, D. G., Adam, M. A., & Miller, A. D. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.8.4239 · Cited by 893
Fehniger, T. A., Cooper, M. A., Nuovo, G. J., Cella, M., Facchetti, F., Colonna, M., & Caligiuri, M. A. (2003) · Blood · doi:10.1182/blood-2002-09-2876 · Cited by 857
Targeting natural killer cells and natural killer T cells in cancer
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., & Brossay, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3174 · Cited by 850
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 824
Self-citationIrving, B. A., & Weiss, A. (1991) · Cell · doi:10.1016/0092-8674(91)90314-o · Cited by 805
An inducible caspase 9 safety switch for T-cell therapy
Straathof, K. C., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 742
Björkström, N. K., Riese, P., Heuts, F., Andersson, S., Fauriat, C., Ivarsson, M. A., Björklund, A. T., Flodström-Tullberg, M., Michaëlsson, J., Rottenberg, M. E., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281675 · Cited by 734
Gong, J.-H., Maki, G., & Klingemann, H.-G. (1994) · PubMed · Cited by 723
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Brandt, C. S., Baratin, M., Yi, E. C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C. D., Kaifu, T., Chabannon, C., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090681 · Cited by 706
Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
Brudno, J. N., Somerville, R. P. T., Shi, V., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea-Banacloche, J. C., Pavletic, S. Z., Hickstein, D. D., Lu, T. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5929 · Cited by 605
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86721 · Cited by 500
Self-citationNatural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., & Caligiuri, M. A. (2002) · Blood · doi:10.1182/blood-2002-02-0350 · Cited by 491
Ciceri, F., Bonini, C., Stanghellini, M. T. L., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70074-9 · Cited by 488
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Finney, H. M., Akbar, A. N., & Lawson, A. D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.104 · Cited by 467
Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462
Fitzgerald, J. C., Weiss, S. L., Maude, S. L., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., Shaw, P., Berg, R. A., June, C. H., Porter, D. L., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002053 · Cited by 459
Steinle, A., Li, P., Morris, D. L., Groh, V., Lanier, L. L., Strong, R. K., & Spies, T. (2001) · Immunogenetics · doi:10.1007/s002510100325 · Cited by 454
Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 443
Tagaya, Y., Bamford, R. N., DeFilippis, A. P., & Waldmann, T. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80246-0 · Cited by 440
Chu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Geller, M. A., Cooley, S., Judson, P. L., Ghebre, R., Carson, L. F., Argenta, P. A., Jonson, A. L., Panoskaltsis-Mortari, A., Curtsinger, J., McKenna, D., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2010.515582 · Cited by 436
Bachanova, V., Cooley, S., Defor, T. E., Verneris, M. R., Zhang, B., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lewis, D., Hippen, K., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532531 · Cited by 435
Cooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K., Klein, J., Le, C. T., Marsh, S. G. E., Guethlein, L. A., Parham, P., Miller, J. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-171926 · Cited by 434
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008) · Cytotherapy · doi:10.1080/14653240802301872 · Cited by 434
HLA-C–Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1
Venstrom, J. M., Pittari, G., Gooley, T. A., Chewning, J. H., Spellman, S., Haagenson, M., Gallagher, M. M., Malkki, M., Petersdorf, E., Dupont, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200503 · Cited by 429
Wang, Q.-S., Wang, Y., Lv, H.-Y., Han, Q.-W., Fan, H., Guo, B., Wang, L.-L., & Han, W.-D. (2015) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 418
Knorr, D. A., Ni, Z., Hermanson, D., Hexum, M. K., Bendzick, L., Cooper, L. J. N., Lee, D. A., & Kaufman, D. S. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0084 · Cited by 415
MICA Engagement by Human Vγ2Vδ2 T Cells Enhances Their Antigen-Dependent Effector Function
Das, H., Groh, V., Kuijl, C., Sugita, M., Morita, C. T., Spies, T., & Bukowski, J. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00168-6 · Cited by 409
Killer immunoglobulin-like receptors
Moretta, L., & Moretta, A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.010 · Cited by 409
Natural killer cell receptors.
Yokoyama, W. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80168-4 · Cited by 408
Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M. R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329508 · Cited by 406
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
Olson, J. A., Leveson-Gower, D. B., Gill, S., Baker, J., Beilhack, A., & Negrin, R. S. (2010) · Blood · doi:10.1182/blood-2009-05-222190 · Cited by 384
Pogge von Strandmann, E., Simhadri, V. R., von Tresckow, B., Sasse, S., Reiners, K. S., Hansen, H. P., Rothe, A., Böll, B., Simhadri, V. L., Borchmann, P., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.10.010 · Cited by 374
Schönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bönig, H., Köhl, U., Kloess, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 348
Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., Victor, A., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 340
Goulmy, E. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb00978.x · Cited by 331
Chang, Y.-H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3558 · Cited by 329
NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Suck, G., Odendahl, M., Nowakowska, P., Seidl, C., Wels, W. S., Klingemann, H. G., & Tonn, T. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1761-x · Cited by 328
Interleukin-2, Interleukin-15, and Their Roles in Human Natural Killer Cells
Becknell, B., & Caligiuri, M. A. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(04)86006-1 · Cited by 325
Asai, O., Longo, D. L., Tian, Z. G., Hornung, R. L., Taub, D. D., Ruscetti, F. W., & Murphy, W. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1268 · Cited by 301
Yokoyama, W. M. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80036-0 · Cited by 299
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Algarra, I., Garc�a-Lora, A., Cabrera, T., Ruiz-Cabello, F., & Garrido, F. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0517-9 · Cited by 293
Tiberghien, P. (2001) · Blood · doi:10.1182/blood.v97.1.63 · Cited by 289
Fillat, C., Carrio, M., Cascante, A., & Sangro, B. (2003) · Current Gene Therapy · doi:10.2174/1566523033347426 · Cited by 287
Iliopoulou, E. G., Kountourakis, P., Karamouzis, M. V., Doufexis, D., Ardavanis, A., Baxevanis, C. N., Rigatos, G., Papamichail, M., & Perez, S. A. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0904-3 · Cited by 277
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Rezvani, K., & Rouce, R. H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00578 · Cited by 272
Self-citationCaligiuri, M. A., Murray, C., Robertson, M. J., Wang, E., Cochran, K., Cameron, C., Schow, P., Ross, M. E., Klumpp, T. R., & Soiffer, R. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116161 · Cited by 269
Driving gene-engineered T cell immunotherapy of cancer
Johnson, L. A., & June, C. H. (2017) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 268
Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92
Tonn, T., Becker, S., Esser, R., Schwabe, D., & Seifried, E. (2001) · Journal of Hematotherapy & Stem Cell Research · doi:10.1089/15258160152509145 · Cited by 267
Jiang, H., Zhang, W., Shang, P., Zhang, H., Fu, W., Ye, F., Zeng, T., Huang, H., Zhang, X., Sun, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.001 · Cited by 267
Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
Factors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92
Maki, G., Klingemann, H.-G., Martinson, J. A., & Tam, Y. K. (2001) · Journal of Hematotherapy & Stem Cell Research · doi:10.1089/152581601750288975 · Cited by 262
Burns, L. J., Weisdorf, D. J., DeFor, T. E., Vesole, D. H., Repka, T. L., Blazar, B. R., Burger, S. R., Panoskaltsis-Mortari, A., Keever-Taylor, C. A., Zhang, M.-J., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704086 · Cited by 252
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Töpfer, K., Cartellieri, M., Michen, S., Wiedemuth, R., Müller, N., Lindemann, D., Bachmann, M., Füssel, M., Schackert, G., & Temme, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400330 · Cited by 249
Willemze, R., Rodrigues, C. A., Labopin, M., Sanz, G., Michel, G., Socié, G., Rio, B., Sirvent, A., Renaud, M., Madero, L., et al. (2009) · Leukemia · doi:10.1038/leu.2008.365 · Cited by 245
Jinushi, M., Takehara, T., Tatsumi, T., Kanto, T., Groh, V., Spies, T., Kimura, R., Miyagi, T., Mochizuki, K., Sasaki, Y., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10966 · Cited by 244
Chen, X., Han, J., Chu, J., Zhang, L., Zhang, J., Chen, C., Chen, L., Wang, Y., Wang, H., Yi, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8526 · Cited by 242
Stringaris, K., Sekine, T., Khoder, A., Alsuliman, A., Razzaghi, B., Sargeant, R., Pavlu, J., Brisley, G., de Lavallade, H., Sarvaria, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.087536 · Cited by 231
Self-citationRomanski, A., Uherek, C., Bug, G., Seifried, E., Klingemann, H., Wels, W. S., Ottmann, O. G., & Tonn, T. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12810 · Cited by 220
Fully human CD19-specific chimeric antigen receptors for T-cell therapy
Sommermeyer, D., Hill, T., Shamah, S. M., Salter, A. I., Chen, Y., Mohler, K. M., & Riddell, S. R. (2017) · Leukemia · doi:10.1038/leu.2017.57 · Cited by 220
Call, M. E., Schnell, J. R., Xu, C., Lutz, R. A., Chou, J. J., & Wucherpfennig, K. W. (2006) · Cell · doi:10.1016/j.cell.2006.08.044 · Cited by 219
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
Lapteva, N., Durett, A. G., Sun, J., Rollins, L. A., Huye, L. L., Fang, J., Dandekar, V., Mei, Z., Jackson, K., Vera, J., et al. (2012) · Cytotherapy · doi:10.3109/14653249.2012.700767 · Cited by 216
Müller, T., Uherek, C., Maki, G., Chow, K. U., Schimpf, A., Klingemann, H.-G., Tonn, T., & Wels, W. S. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0383-3 · Cited by 212
Tam, Y. K., Maki, G., Miyagawa, B., Hennemann, B., Tonn, T., & Klingemann, H.-G. (1999) · Human Gene Therapy · doi:10.1089/10430349950018030 · Cited by 203
Shah, N., Martin-Antonio, B., Yang, H., Ku, S., Lee, D. A., Cooper, L. J. N., Decker, W. K., Li, S., Robinson, S. N., Sekine, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076781 · Cited by 199
Self-citationSoiffer, R., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P., Daley, J., & Ritz, J. (1992) · Blood · doi:10.1182/blood.v79.2.517.517 · Cited by 197
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., Kiessling, R., Blankenstein, T., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 197
Waldmann, T. A., Lugli, E., Roederer, M., Perera, L. P., Smedley, J. V., Macallister, R. P., Goldman, C. K., Bryant, B. R., Decker, J. M., Fleisher, T. A., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311456 · Cited by 195
Boissel, L., Betancur, M., Lu, W., Krause, D., Van Etten, R., Wels, W., & Klingemann, H. (2013) · OncoImmunology · doi:10.4161/onci.26527 · Cited by 194
Esser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D., Aperlo‐Iffland, C., Huston, J. S., Uherek, C., Schönfeld, K., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01343.x · Cited by 188
Imamura, M., Shook, D., Kamiya, T., Shimasaki, N., Chai, S. M. H., Coustan-Smith, E., Imai, C., & Campana, D. (2014) · Blood · doi:10.1182/blood-2014-02-556837 · Cited by 188
Oelsner, S., Friede, M. E., Zhang, C., Wagner, J., Badura, S., Bader, P., Ullrich, E., Ottmann, O. G., Klingemann, H., Tonn, T., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2016.10.009 · Cited by 188
Lanitis, E., Poussin, M., Hagemann, I. S., Coukos, G., Sandaltzopoulos, R., Scholler, N., & Powell, D. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.256 · Cited by 187
Genßler, S., Burger, M. C., Zhang, C., Oelsner, S., Mildenberger, I., Wagner, M., Steinbach, J. P., & Wels, W. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1119354 · Cited by 187
Budde, L. E., Berger, C., Lin, Y., Wang, J., Lin, X., Frayo, S. E., Brouns, S. A., Spencer, D. M., Till, B. G., Jensen, M. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082742 · Cited by 186
Sahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
Chen, K. H., Wada, M., Pinz, K. G., Liu, H., Lin, K.-W., Jares, A., Firor, A. E., Shuai, X., Salman, H., Golightly, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.8 · Cited by 184
Gill, S., Vasey, A. E., De Souza, A., Baker, J., Smith, A. T., Kohrt, H. E., Florek, M., Gibbs, K. D., Tate, K., Ritchie, D. S., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415364 · Cited by 183
Jochems, C., Hodge, J. W., Fantini, M., Fujii, R., Morillon, Y. M., Greiner, J. W., Padget, M. R., Tritsch, S. R., Yok Tsang, K., Campbell, K. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13411 · Cited by 182
Dalle, J.-H., Menezes, J., Wagner, É., Blagdon, M., Champagne, J., Champagne, M. A., & Duval, M. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000156501.55431.20 · Cited by 180
Gumperz, J. E., Barber, L. D., Valiante, N. M., Percival, L., Phillips, J. H., Lanier, L. L., & Parham, P. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.11.5237 · Cited by 179
Boyiadzis, M., Agha, M., Redner, R. L., Sehgal, A., Im, A., Hou, J.-Z., Farah, R., Dorritie, K. A., Raptis, A., Lim, S. H., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.008 · Cited by 178
Luevano, M., Daryouzeh, M., Alnabhan, R., Querol, S., Khakoo, S., Madrigal, A., & Saudemont, A. (2012) · Human Immunology · doi:10.1016/j.humimm.2011.12.015 · Cited by 177
Shimasaki, N., Fujisaki, H., Cho, D., Masselli, M., Lockey, T., Eldridge, P., Leung, W., & Campana, D. (2012) · Cytotherapy · doi:10.3109/14653249.2012.671519 · Cited by 177
Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy
Pedroza-Pacheco, I., Madrigal, A., & Saudemont, A. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.2 · Cited by 176
Chu, Y., Hochberg, J., Yahr, A., Ayello, J., van de Ven, C., Barth, M., Czuczman, M., & Cairo, M. S. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0114 · Cited by 174
A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors
Boyington, J. C., & Sun, P. D. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00030-5 · Cited by 172
Boissel, L., Betancur, M., Wels, W. S., Tuncer, H., & Klingemann, H. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.024 · Cited by 166
Bloushtain, N., Qimron, U., Bar-Ilan, A., Hershkovitz, O., Gazit, R., Fima, E., Korc, M., Vlodavsky, I., Bovin, N. V., & Porgador, A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2392 · Cited by 165
Sutlu, T., Nyström, S., Gilljam, M., Stellan, B., Applequist, S. E., & Alici, E. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.080 · Cited by 162
NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation
Ruggeri, L., Mancusi, A., Burchielli, E., Capanni, M., Carotti, A., Aloisi, T., Aversa, F., Martelli, M. F., & Velardi, A. (2008) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2007.06.029 · Cited by 161
Rouce, R. H., Shaim, H., Sekine, T., Weber, G., Ballard, B., Ku, S., Barese, C., Murali, V, Wu, M.-F., Liu, H., et al. (2016) · Leukemia · doi:10.1038/leu.2015.327 · Cited by 161
Self-citationShaffer, B. C., Luduec, J.-B. L., Forlenza, C. J., Jakubowski, A. A., Perales, M., Young, J. W., & Hsu, K. C. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.12.028 · Cited by 151
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Marsh, S. G. E., Spellman, S. R., Haagenson, M. D., Saeturn, K., Ladner, M. B., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302517 · Cited by 148
Oevermann, L., Michaelis, S. U., Mezger, M., Lang, P., Toporski, J., Bertaina, A., Zecca, M., Moretta, L., Locatelli, F., & Handgretinger, R. (2014) · Blood · doi:10.1182/blood-2014-03-565069 · Cited by 146
Boissel, L., Betancur, M., Lu, W., Wels, W. S., Marino, T., Etten, R. A. V., & Klingemann, H. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.634048 · Cited by 146
Li, L., Liu, L. N., Feller, S., Allen, C., Shivakumar, R., Fratantoni, J. C., Wolfraim, L. A., Fujisaki, H., Campana, D., Chopas, N., et al. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.61 · Cited by 144
Koehl, U., Brehm, C., Huenecke, S., Zimmermann, S. Y., Kloeß, S., Bremm, M., Ullrich, E., Soerensen, J., Quaiser, A., Erben, S., et al. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00118 · Cited by 143
Alkins, R. D., Burgess, A., Kerbel, R. S., Wels, W. S., & Hynynen, K. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov318 · Cited by 142
Harel‐Bellan, A., Quillet‐Mary, A., Marchiol, C., DeMars, R., Tursz, T., & FRADELIZI, D. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.15.5688 · Cited by 142
Face off — the interplay between activating and inhibitory immune receptors
Lanier, L. L. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00222-3 · Cited by 139
Chen, X., Allan, D., Krzewski, K., Ge, B.-X., Kopcow, H. D., & Strominger, J. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604236103 · Cited by 134
Abo, T., Miller, C. A., & Balch, C. M. (1984) · European Journal of Immunology · doi:10.1002/eji.1830140707 · Cited by 132
Yoon, S. R., Lee, Y. S., Yang, S., Ahn, K. H., Lee, J.-H., Lee, J.-H., Kim, D. Y., Kang, Y., Jeon, M., Seol, M., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.304 · Cited by 129
Wilber, A. C., Linehan, J. L., Tian, X., Woll, P. S., Morris, J. K., Belur, L. R., McIvor, R. S., & Kaufman, D. S. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0026 · Cited by 129
Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells
Anurathapan, U., Chan, R. C., Hindi, H. F., Mucharla, R., Bajgain, P., Hayes, B. C., Fisher, W. E., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.262 · Cited by 128
Construction and evaluation of a novel humanized HER2-specific chimeric receptor
Sun, M., Shi, H., Liu, C., Liu, J., Liu, X., & Sun, Y. (2014) · Breast Cancer Research · doi:10.1186/bcr3674 · Cited by 125
Simplified process for the production of anti–CD19-CAR–engineered T cells
Tumaini, B., Lee, D. W., Lin, T. L., Castiello, L., Stroncek, D. F., Mackall, C. L., Wayne, A. S., & Sabatino, M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.003 · Cited by 123
Improving the safety of cell therapy with the TK-suicide gene
Greco, R., Oliveira, G., Stanghellini, M. T. L., Vago, L., Bondanza, A., Peccatori, J., Cieri, N., Marktel, S., Mastaglio, S., Bordignon, C., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00095 · Cited by 122
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
Chen, K. H., Wada, M., Firor, A. E., Pinz, K. G., Jares, A., Liu, H., Salman, H., Golightly, M. G., Lan, F., Jiang, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11019 · Cited by 118
Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer
Davis, Z., Felices, M., Verneris, M. R., & Miller, J. S. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000156 · Cited by 114
Nagashima, S., Mailliard, R. B., Kashii, Y., et al. (1998) · Blood · doi:10.1182/blood.v91.10.3850 · Cited by 113
Ni, Z., Knorr, D. A., Bendzick, L. E., Allred, J. R., & Kaufman, D. S. (2013) · Stem Cells · doi:10.1002/stem.1611 · Cited by 105
Boyington, J. C., Brööks, A. G., & Sun, P. D. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1810105.x · Cited by 104
Complications of donor apheresis
Winters, J. L. (2006) · Journal of Clinical Apheresis · doi:10.1002/jca.20039 · Cited by 103
Miller, J. S., Tessmer-Tuck, J. A., Pierson, B. A., Weisdorf, D. J., McGlave, P. B., Blazar, B. R., Katsanis, E., Verfaillie, C. M., LEBKOWSKI, J. S., Radford, J., et al. (1997) · PubMed · Cited by 102
Interleukin 2 in Cancer Therapy
Antony, G. K., & Dudek, A. Z. (2012) · Current Medicinal Chemistry · doi:10.2174/092986710793176410 · Cited by 102
Stringaris, K., Adams, S., Uribe, M. R., Eniafe, R., Wu, C. O., Savani, B., & Barrett, A. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.004 · Cited by 97
Natural killer cells in the treatment of high-risk acute leukaemia
Locatelli, F., Moretta, F., Brescia, L. P., & Merli, P. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.004 · Cited by 94
Song, D.-G., Ye, Q., Poussin, M., Liu, L., Figini, M., & Powell, D. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4071 · Cited by 94
Wang, Y., Xu, H., Zheng, X., Wei, H., Sun, R., & Tian, Z. (2007) · PubMed · Cited by 93
Insertional oncogenesis in gene therapy: how much of a risk?
Sadelain, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302243 · Cited by 92
Lin, P. Y., Lin, Y., Lennon, D. P., Correa, D., SCHLUCHTER, M. D., & Caplan, A. I. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0086 · Cited by 92
Meyer, S. D. D., Vanhoorelbeke, K., Chuah, M., Pareyn, I., Gillijns, V., Hebbel, R., Collen, D., Deckmyn, H., & VandenDriessche, T. (2006) · Blood · doi:10.1182/blood-2005-09-3605 · Cited by 91
Zhao, Q., Ahmed, M., Tassev, D. V., Hasan, A., Kuo, T.-Y., Guo, H.-F., O’reilly, R. J., & Cheung, N. K. (2015) · Leukemia · doi:10.1038/leu.2015.125 · Cited by 85
Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D
Wang, Z., Guo, L., Song, Y., Zhang, Y., Lin, D., Hu, B., Mei, Y., Sandikin, D., & Liu, H. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1959-1 · Cited by 84
CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells.
Moingeon, P. E., Lucich, J. L., McConkey, D. J., Letourneur, F., MALISSEN, B., Kochan, J. P., Chang, H. C., Rodewald, H.-R., & Reinherz, E. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.4.1492 · Cited by 82
Moderate and severe adverse events associated with apheresis donations: incidences and risk factors
Yuan, S., Ziman, A. F., Smeltzer, B., Lü, Q., & Goldfinger, D. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02443.x · Cited by 78
Magalhaes-Silverman, M. D., Donnenberg, A. D., Lembersky, B. C., Elder, E. M., LISTER, J. W., Rybka, W. B., Whiteside, T. L., & Ball, E. D. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200001000-00018 · Cited by 78
LISTER, J. W., Rybka, W. B., Donnenberg, A. D., et al. (1995) · PubMed · Cited by 77
Tumor escape from immune surveillance.
Costello, R. T., Gastaut, J. A., & Olive, D. (1999) · PubMed · Cited by 74
Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
Tassev, D. V., Cheng, M., & Cheung, N. K. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.66 · Cited by 72
Meropol, N. J., Porter, M., Blumenson, L. E., Lindemann, M. J., Perez, R. P., Vaickus, L., Loewen, G., Creaven, P. J., Wilkes, K. A., Giedlin, M. A., et al. (1996) · PubMed · Cited by 70
Liu, H., Yang, B. Y., Sun, T., Lin, L., Hu, Y., Deng, M., Yang, J., Liu, T., Li, J., Sun, S., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3548 · Cited by 68
Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
Davies, J. O. J., Stringaris, K., Barrett, A. J., & Rezvani, K. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.03.009 · Cited by 65
Self-citationThe quantity and duration of FcRγ signals determine mast cell degranulation and survival
Yamasaki, S., Ishikawa, E., Kohno, M., & Saito, T. (2003) · Blood · doi:10.1182/blood-2003-08-2944 · Cited by 62
Fujiwara, S., Akiyama, M., Yamakido, M., Toshio, S., Kyoko, K., Hakoda, M., Kyoizumi, S., & Jones, S. L. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90084-0 · Cited by 61
Sekine, T., Marin, D., Cao, K., Li, L., Mehta, P., Shaim, H., Sobieski, C. E., Jones, R. B., Oran, B., Hosing, C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-706317 · Cited by 61
Self-citationDAP12: a key accessory protein for relaying signals by Natural Killer cell receptors
Campbell, K. S., & Colonna, M. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00022-9 · Cited by 56
Transmembrane Sequences Are Determinants of Immunoreceptor Signaling
Gosse, J. A., Wagenknecht-Wiesner, A., Holowka, D., & Baird, B. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2123 · Cited by 55
Domogala, A., Madrigal, J. A., & Saudemont, A. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.02.008 · Cited by 52
Chen, Y., You, F., Jiang, L., Li, J., Zhu, X., Bao, Y., Sun, X., Tang, X., Meng, H., An, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16201 · Cited by 51
Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells
Konstantinidis, K. V., Alici, E., Aints, A., Christensson, B., Ljunggren, H., & Dilber, M. S. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.11.003 · Cited by 47
Hsieh, Y., Aggarwal, P., Cirelli, D. J., Gu, L., Surowy, T. K., & Mozier, N. M. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.12.002 · Cited by 43
A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells
Kobayashi, E., Kishi, H., Ozawa, T., Hamana, H., Nakagawa, H., Jin, A., Lin, Z., & Muraguchi, A. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.024 · Cited by 39
Multicolor-FISH analysis of a natural killer cell line (NK-92)
MacLeod, R. A. F., Nagel, S., Kaufmann, M., Greulich‐Bode, K. M., & Drexler, H. G. (2002) · Leukemia Research · doi:10.1016/s0145-2126(02)00055-3 · Cited by 39
Voshol, H., Dullens, H. F. J., Otter, W. D., & Vliegenthart, J. F. G. (1993) · Journal of Immunological Methods · doi:10.1016/0022-1759(93)90102-d · Cited by 36
Lentiviral Gene Transduction of Mouse and Human Stem Cells
Ye, Z., Yu, X., & Cheng, L. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-182-6_17 · Cited by 33
Cancer immunotherapy: are we there yet?
Li, Z., Chen, L., & Rubinstein, M. P. (2013) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-2-33 · Cited by 32
Li, J., Liu, H., Li, L., Wu, H., Wang, C., YAN, Z., Wang, Y., Su, C., Jin, H., ZHOU, F., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.2217 · Cited by 28
Clemenceau, B., Valsesia‐Wittmann, S., Jallas, A.-C., Vivien, R., Rousseau, R. F., Marabelle, A., Caux, C., & Vié, H. (2015) · Journal of Immunology Research · doi:10.1155/2015/482089 · Cited by 27
Willemze, R., Ruggeri, A., Purtill, D., Arrais‐Rodrigues, C., Gluckman, É., & Rocha, V. (2010) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2010.05.005 · Cited by 23
Supply of promising T cell therapy is strained
Couzin-Frankel, J. (2017) · Science · doi:10.1126/science.356.6343.1112 · Cited by 13
Cited by
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,227
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Engineering and Design of Chimeric Antigen Receptors
Guedan, S., Calderon, H., Posey, A. D., & Maus, M. V. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.009 · Cited by 453
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Xiao, L., Cen, D., Gan, H., Sun, Y., Huang, N., Xiong, H., Jin, Q., Su, L., Liu, X., Wang, K., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.011 · Cited by 323
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Souza-Fonseca-Guimaraes, F., Cursons, J., & Huntington, N. D. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.12.003 · Cited by 279
Metadata
- Authors
- Mehta, R. S., & Rezvani, K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-02-15
- Volume
- 9
- Pages
- 283-283
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2791974013
- Cited by
- 259
- References
- 199
- FWCI
- 13.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.